Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy

Stock News08-03

The company Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in patients with advanced or metastatic colorectal cancer.

This initiated SYS6090-008 study is an open-label, multicenter Phase Ib/II clinical trial designed to assess the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in colorectal cancer patients. Moving forward, based on the results of this study, the company plans to advance the Phase III confirmatory clinical trial for SYS6090 combination therapy in colorectal cancer patients, further validating the clinical value of this treatment approach. Currently, patient recruitment and screening for the SYS6090-008 study are actively progressing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196848313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196848313","market":"sg","top_or_hot":-1,"title":"Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy","media":"Stock News","content":"<p>The company <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in patients with advanced or metastatic colorectal cancer.<br><br>This initiated SYS6090-008 study is an open-label, multicenter Phase Ib/II clinical trial designed to assess the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in colorectal cancer patients. Moving forward, based on the results of this study, the company plans to advance the Phase III confirmatory clinical trial for SYS6090 combination therapy in colorectal cancer patients, further validating the clinical value of this treatment approach. Currently, patient recruitment and screening for the SYS6090-008 study are actively progressing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The company <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in patients with advanced or metastatic colorectal cancer.<br><br>This initiated SYS6090-008 study is an open-label, multicenter Phase Ib/II clinical trial designed to assess the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in colorectal cancer patients. Moving forward, based on the results of this study, the company plans to advance the Phase III confirmatory clinical trial for SYS6090 combination therapy in colorectal cancer patients, further validating the clinical value of this treatment approach. Currently, patient recruitment and screening for the SYS6090-008 study are actively progressing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"","article_id":"1196848313","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196848313","pubTimestamp":1785746310,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The company Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BMED":"iShares Health Innovation Active ETF","BK0226":"食品制造","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"石药创新药启动SYS6090联合疗法Ib/II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"BMED":1,"PSYK":1},"content_text":"The company Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in patients with advanced or metastatic colorectal cancer.This initiated SYS6090-008 study is an open-label, multicenter Phase Ib/II clinical trial designed to assess the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in colorectal cancer patients. Moving forward, based on the results of this study, the company plans to advance the Phase III confirmatory clinical trial for SYS6090 combination therapy in colorectal cancer patients, further validating the clinical value of this treatment approach. Currently, patient recruitment and screening for the SYS6090-008 study are actively progressing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196848313","isCrawlerRequest":true}